AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22006379
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ambroxol treatment)
Trial: 19713235
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g psyllium
Trial: 19713235
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g bran
Trial: 19713235
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g placebo (rice flour)
Trial: 17311305
Drug: BCG (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (81 mg)
Trial: 17311305
Drug: BCG (27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (27 mg)
Trial: 17311305
Drug: BCG (27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (27 mg) + IFN-alpha
Trial: 17311305
Drug: BCG (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (81 mg) or BCG (27 mg) + IFN-alpha
Trial: 12086724
Drug: Formulation H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation H
Trial: 12086724
Drug: Formulations F,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations F, G, H and I
Trial: 2698903
Drug: 5682 SE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5682 SE (2 tablets per day for 2 months)
Trial: 2698903
Drug: Diosmin (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diosmin (900 mg per day for 2 months)
Trial: 1190094
Drug: Information condition
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information condition subjects administered the SHSS A in standardized manner
Trial: 1190094
Drug: No information
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No information subjects administered the SHSS A with usual rapport section omitted
Trial: 11706694
Drug: Poly-L-lactic acid
RxNorm normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly-L-lactic acid screws
Trial: 7921429
Drug: Salmeterol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol treatment
Trial: 23446962
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (HPD), 1.2 g·kg BW(-1)·d(-1)
Trial: 23446962
Drug: Normal-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-protein diet (NPD), 0.8 g·kg BW(-1)·d(-1)
Trial: 15257930
Drug: Autologous stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem cell transplantation (ASCT) after induction therapy with idarubicin, cytarabine, and etoposide.
Trial: 15257930
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with idarubicin, cytarabine, and etoposide.
Trial: 29671767
Drug: Whey Protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey Protein Hydrolysate (3.3, 5.0, or 7.5 g of protein)
Trial: 29671767
Drug: Free Amino
RxNorm normalized name: FREE AMINO ACID DIET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free Amino Acid Mixture (2.5 g)
Trial: 27644034
Drug: EBA-175 RII-NG
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBA-175 RII-NG vaccine (5 μg, 20 μg, or 80 μg) administered intramuscularly at 0, 1, and 6 months
Trial: 27644034
Drug: EBA-175 RII-NG
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBA-175 RII-NG vaccine
Trial: 19458364
Drug: Dipyridamole plus
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole plus aspirin (200 mg dipyridamole and 25 mg aspirin, twice daily)
Trial: 15532134
Drug: Transdermal contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal contraceptive patch (20 micrograms of ethinylestradiol and 150 micrograms of norelgestromin)
Trial: 9597955
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (CT) and radiotherapy (RT)
Trial: 7941816
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) intracervically in the evening (10.00 p.m.)
Trial: 7941816
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) intracervically in the morning (6.00 a.m.)
Trial: 7941816
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) in the evening (10.00 p.m.)
Trial: 7941816
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg PGE2 in 2.5 ml Triacetin gel (Prepidil) in the morning (6.00 a.m.)
Trial: 28825515
Drug: Egg-based, trivalent,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg-based, trivalent, inactivated split influenza vaccine
Trial: 25764482
Drug: Topical natamycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical natamycin, 5%
Trial: 25764482
Drug: Topical voriconazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical voriconazole, 1%
Trial: 25764482
Drug: Topical natamycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical natamycin, 5% (subgroup analysis for Fusarium species)
Trial: 25764482
Drug: Topical voriconazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical voriconazole, 1% (subgroup analysis for Fusarium species)
Trial: 25764482
Drug: Topical natamycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical natamycin, 5% (for Aspergillus or other non-Fusarium species)
Trial: 25764482
Drug: Topical voriconazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical voriconazole, 1% (for Aspergillus or other non-Fusarium species)
Trial: 22990223
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of nicotine replacement therapy (NRT)
Trial: 22990223
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of nicotine replacement therapy (NRT)
Trial: 20529203
Drug: Self-management workshop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management workshop (6-week intervention, weekly 2-hour sessions based on cognitive-behavioral principles)
Trial: 15223002
Drug: L-DOPA (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DOPA (400 mg) + CarbiDOPA (100 mg)
Trial: 2434802
Drug: Perindopril (4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4, 8, and 16 mg)
Trial: 30963205
Drug: Dexamethasone 0.1
RxNorm normalized name: dexamethasone 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.1 mg/kg IV
Trial: 24329696
Drug: Estrogen substitution
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen substitution therapy (follow-up study)
Trial: 19339404
Drug: Walnut diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut diet (42.5 g walnuts/10.1 mJ)
Trial: 19339404
Drug: Fish diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish diet (113 g salmon, twice/wk)
Trial: 11730735
Drug: (99m)Tc‐pertechnetate vaginally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (99m)Tc‐pertechnetate vaginally (0.2 mL)
Trial: 11730735
Drug: (99m)Tc‐pertechnetate vaginally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (99m)Tc‐pertechnetate vaginally (0.2 mL) with sealed cervical canal
Trial: 9200272
Drug: Prednisolone 40
RxNorm normalized name: prednisolone 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 40 mg per day
Trial: 8254957
Drug: Breast conserving
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast conserving treatment, quadrantectomy with or without immediate reconstruction, axillary dissection, internal mammary biopsy, and breast irradiation
Trial: 2888736
Drug: Ro 23-0364
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 23-0364 (0.25 mg)
Trial: 2888736
Drug: Ro 23-0364
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 23-0364 (0.5 mg)
Trial: 2888736
Drug: Ro 23-0364
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 23-0364 (1.0 mg)
Trial: 27031850
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with chemotherapy
Trial: 1245939
Drug: Inactivated monovalent
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated monovalent influenza B vaccine (0.25 ml containing 250 chick cell agglutinating units)
Trial: 30663593
Drug: Vincristine 1·4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine 1·4 mg/m2 [maximum 2·0 mg]
Trial: 23112275
Drug: Silicone intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone intranasal septal splint (INS)
Trial: 19736359
Drug: Sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride therapy for 6 months
Trial: 17034955
Drug: Paroxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine treatment for 8 weeks
Trial: 12759221
Drug: TPNGLN (glutamine-supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPNGLN (glutamine-supplemented TPN, 0.4 g.kg‐1.day‐1)
Trial: 12759221
Drug: TPN (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN (conventional parenteral nutrition)
Trial: 8290465
Drug: Povidone-iodine alcoholic
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine alcoholic solution
Trial: 8290465
Drug: Povidone-iodine aqueous
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine aqueous solution
Trial: 3984975
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium loading dose of 550 mg
Trial: 21210268
Drug: Menthol drops
RxNorm normalized name: MENTHOL 20 mg ORAL LOZENGE [Menthol Drops Dollar General Severe 45ct]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menthol drops applied topically with standard therapy (topical clotrimazole)
Trial: 21210268
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with standard therapy (topical clotrimazole)
Trial: 16142002
Drug: Topical gel
RxNorm normalized name: Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel containing gaïazulene and dimeticone
Trial: 2255839
Drug: Ivermectin 150
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 150 mcg/kg
Trial: 20695208
Drug: Cycloferon (injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloferon (injections and tablets)
Trial: 20695208
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with immunomodulators (including cycloferon, galavit, and derinat)
Trial: 18156372
Drug: Prescription only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription only (arm B)
Trial: 16785215
Drug: Symptom-triggered (ST)
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-triggered (ST) dosing of lorazepam based on CIWA-Ar score
Trial: 16785215
Drug: Fixed-schedule (FS)
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-schedule (FS) dosing of lorazepam with tapering over 4 days
Trial: 14605453
Drug: Unconventional anti-cancer
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unconventional anti-cancer drugs
Trial: 10830255
Drug: Systemic corticosteroids
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic corticosteroids administered within the first 2 weeks of life
Trial: 10830255
Drug: Diuretics and
RxNorm normalized name: Low-ceiling diuretics and potassium-sparing agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics and inhaled bronchodilators
Trial: 10830255
Drug: Alpha-1 proteinase
RxNorm normalized name: alpha-1 proteinase inhibitor
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-1 proteinase inhibitor
Trial: 1727807
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg MEL administered daily (days 1-30) for 4 months
Trial: 1727807
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg MEL (days 5-17) and 75 mg MEL combined with 0.3 mg NET
Trial: 6371876
Drug: Trazodone 50-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 50-200 mg once daily for 5 weeks
Trial: 6371876
Drug: Doxepin 25-100
RxNorm normalized name: doxepin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin 25-100 mg once daily for 5 weeks
Trial: 24676877
Drug: Tasisulam sodium
RxNorm normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasisulam sodium (targeting an albumin‐corrected exposure of 1200‐6400 h.μg/mL on day 1)
Trial: 24676877
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m² on days 1, 8, and 15 every 28 days)
Trial: 20178538
Drug: HPV-16/18 AS04-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16/18 AS04-adjuvanted cervical cancer vaccine
Trial: 16101180
Drug: Docetaxel 60
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m2 i.v. followed by irinotecan 200 mg/m2 i.v. on day 1 with rhG-CSF support from days 2 to 6, every 3 weeks
Trial: 11834957
Drug: Cidofovir Treatment
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cidofovir Treatment (CT)
Trial: 11834957
Drug: Surgical-Cidofovir Treatment
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgical-Cidofovir Treatment (SCT)
Trial: 7717184
Drug: PETN (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PETN (150 mg b.i.d.)
Trial: 2149509
Drug: Buserelin (nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin (nasal spray, 3 daily doses of 400 micrograms) combined with cyproterone acetate (CPA, 3 daily doses of 50 mg orally for 2 weeks)
Trial: 2149509
Drug: Orchidectomy (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orchidectomy (standard androgen-deprivative therapy)
Trial: 25479571
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g protein per kg body weight per day
Trial: 25479571
Drug: 1.6 g
RxNorm normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 g protein per kg body weight per day
Trial: 25479571
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g protein per kg body weight per day
Trial: 9555667
Drug: Exogenous norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous norepinephrine (NE) at pressor doses (delta MAP = 20 mmHg)
Trial: 7995145
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy (20 Gy total, divided into four daily fractions of 5 Gy each)
Trial: 2908216
Drug: Chlordesmethyldiazepam 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordesmethyldiazepam 0.1 mg/kg i.v. (group C)
Trial: 2908216
Drug: Sodium thiopental
RxNorm normalized name: Thiopental Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium thiopental 5 mg/kg i.v. (group T)
Trial: 24646366
Drug: Daily interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interval training until a 25% decrement in time-to-fatigue performance (Study 1)
Trial: 22505376
Drug: Topical isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical isosorbide dinitrate 10%
Trial: 22505376
Drug: Topical isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical isosorbide dinitrate 5%
Trial: 22505376
Drug: Symptomatic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatments (control group)
Trial: 17613297
Drug: Intravenous ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ghrelin (5 pmol/kg/min) infusion
Trial: 8335833
Drug: Captopril (sulfhydryl‐containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (sulfhydryl‐containing angiotensin‐converting enzyme inhibitor)
Trial: 8335833
Drug: Intracoronary nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary nitroglycerin (1‐ to 20‐micrograms doses)
Trial: 2445091
Drug: YM-12617 (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM-12617 (0.2 mg)
Trial: 2445091
Drug: YM-12617 (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM-12617 (0.4 mg)
Trial: 2967855
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide infusion (0.3 micrograms/kg per min)
Trial: 2967855
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide infusion (0.1 microgram/kg per min)
Trial: 31517396
Drug: Insulin‐like growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin‐like growth factor binding protein 1
Trial: 31517396
Drug: Insulin‐like growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin‐like growth factor binding protein 5
Trial: 26051546
Drug: Conventional method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional method (custom tray with impression compound and silicone)
Trial: 11587609
Drug: Mitomycin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin (0.4 mg/mL, 2 mL solution applied for 2 minutes)
Trial: 9156373
Drug: sirolimus (0.5‐6.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sirolimus (0.5‐6.5 mg/m2/12 hr)
Trial: 3331375
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) and Tamoxifen (TAM)
Trial: 23370582
Drug: Water-based exercise
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-based exercise (at least twice-weekly for 8 weeks)
Trial: 8408733
Drug: Quinidine sulfate
RxNorm normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulfate (200 mg orally)
Trial: 8408733
Drug: Nifedipine-quinidine combination
RxNorm normalized name: nifedipine, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine-quinidine combination
Trial: 3760461
Drug: Bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (5 mg/day for 5 days)
Trial: 30333336
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (3 g in 100 ml saline solution)
Trial: 30333336
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (placebo, 100 ml)
Trial: 22349673
Drug: Ketamine-propofol-dexmedetomidine combination
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine-propofol-dexmedetomidine combination (KPD group, n = 30)
Trial: 22349673
Drug: Ketamine-propofol combination
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine-propofol combination (KP group, n = 30)
Trial: 17509069
Drug: Metformin (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (titrated to 2000 mg daily)
Trial: 12424384
Drug: Moderate doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate doses of alcohol
Trial: 9523805
Drug: 2.5 ml
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml 2% lidocaine in 7.5% glucose
Trial: 2672786
Drug: Methylphenidate (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (0.3 mg/kg per dose, administered at 8 AM and 12 PM on school days)
Trial: 1103209
Drug: marihuana containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: marihuana containing 20 mg Delta‐9‐tetrahydrocannabinol